MCM
VRTX icon

Mattern Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Mattern Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.73M Buy
3,877
+188
+5% +$87.7K 0.21% 93
2025
Q4 		$1.67M Buy
3,689
+377
+11% +$162K 0.2% 89
2025
Q3 		$1.3M Buy
3,312
+980
+42% +$410K 0.15% 108
2025
Q2 		$1.04M Buy
2,332
+396
+20% +$182K 0.12% 109
2025
Q1 		$939K Buy
1,936
+63
+3% +$29.4K 0.12% 97
2024
Q4 		$754K Buy
1,873
+144
+8% +$66.7K 0.1% 105
2024
Q3 		$804K Buy
1,729
+142
+9% +$68.2K 0.1% 98
2024
Q2 		$744K Buy
1,587
+288
+22% +$125K 0.1% 97
2024
Q1 		$543K Buy
+1,299
New +$549K 0.07% 105

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Mattern Capital Management's VRTX Position: Q1 2026 in Review

Mattern Capital Management increased its Vertex Pharmaceuticals (VRTX) stake by 5.1% in Q1 2026, buying an estimated $87.7K and bringing the position to 3,877 shares worth $1.73M. The position accounts for 0.21% of the portfolio, ranked #93.

Mattern Capital Management first reported a position in VRTX in Q1 2024 and has held it in 9 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Mattern Capital Management held 3,877 shares of Vertex Pharmaceuticals worth $1.73M as of Q1 2026.
  • Mattern Capital Management bought 188 Vertex Pharmaceuticals shares in Q1 2026, an estimated $87.7K.
  • Vertex Pharmaceuticals made up 0.21% of Mattern Capital Management's portfolio in Q1 2026, its #93 holding.
  • Mattern Capital Management first reported a position in Vertex Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Mattern Capital Management's 13F filing for Q1 2026, filed 4 May 2026.